Skip to main content
Clinical Trials/NCT03558373
NCT03558373
Completed
Not Applicable

The Adherence of Immunosuppressive Therapy Including Tacrolimus Once Daily in a Cohort of Kidney Transplant Recipients: an Italian Prospective Observational Study

Chiesi Farmaceutici S.p.A.12 sites in 1 country158 target enrollmentJuly 31, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Kidney Transplant
Sponsor
Chiesi Farmaceutici S.p.A.
Enrollment
158
Locations
12
Primary Endpoint
Non aderence
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Non-adherence is widespread in the transplant community. Addressing issues associated with non-adherence remains a key challenge in transplantation, in part due to the difficulty in assessing its prevalence, as there is currently no 'gold standard' for use in routine clinical practice.

The purpose of this study is to evaluate the non-adherence to immunosuppressive therapy, including tacrolimus once-daily, among Italian kidney transplant recipients receiving. Along with non-adherence evaluation, possible factors related to NA will be investigated (patient-related, condition/disease-related, therapy/treatment-related, etc.).

Registry
clinicaltrials.gov
Start Date
July 31, 2018
End Date
February 26, 2020
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Non aderence

Time Frame: 6 months

Proportion of non-adherent patients to immunosuppressive therapy as measured by the Basel Assessment of Adherence with Immunosuppressives Scale (BAASIS©-interview). The BAASIS© consists of four items (with a 6-point scale for responses ranging from never (0) to every day (5)) measuring patients' taking, skipping (or drug holidays), timing (\>2 hrs from prescribed time) and dose reduction of drugs. An affirmative answer to any of the first 4 questions results in assignment to the non-adherent group.

Secondary Outcomes

  • BAASIS evaluation(Baseline)
  • Graft failure(Baseline and 6 months)
  • BMQ score(Baseline and 6 months)
  • Clinical informations as for clinical practice(Baseline and 6 months)
  • ACCEPT score(Baseline and 6 months)
  • Rejections(Baseline and 6 months)
  • Adverse events(Baseline and 6 months)
  • Infections(Baseline and 6 months)
  • Healthcare cost(6 months)
  • Patients characteristics(Baseline)
  • Immunosuppressive treatments(Baseline and 6 months)

Study Sites (12)

Loading locations...

Similar Trials